A Phase 3 interventional study of Nebivolol, Valsartan and Hydrochlorothiazide in Hypertension, sponsored by Forest Laboratories. Completed at 135 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-04.
Sponsored by Forest Laboratories · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 812 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Forest Laboratories is the lead sponsor of 165 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Nebivolol and Valsartan free tablet combination
Drug: Nebivolol, Valsartan and Hydrochlorothiazide
Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Adverse Event Recording
Time frame: From Baseline to Week 53 (Visit 16)
Diastolic Blood Pressure (DBP).
Time frame: From Baseline to Week 52 (Visit 15)
Systolic Blood Pressure (SBP)
Time frame: From Baseline to Week 52 (Visit 15)
Showing the first 100 of 135 sites.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Forest Laboratories